1)Gürdal C, Saraç O, Genç I et al:Ocular surface and dry eye in Graves' disease. Curr Eye Res 36:8-13, 2011
2)Xu N, Huang DP, Yang HS et al:Ocular surface characteristics and impression cytology in patients with active versus inactive thyroid eye disease. Yan Ke Xue Bao 27:64-68, 2012
3)Ebner R:Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol 13:258-261, 1993
4)Chee E, Chee SP:Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease:a case series. Eye 22:311-315, 2008.
5)木村亜紀子・三村 治・鈴木克彦・他:甲状腺眼症の上眼瞼後退症に対するボツリヌス療法の治療成績.神経眼科 26:50-56,2009
6)Uddin JM, Davies PD:Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 109:1183-1187, 2002
7)Biglan AW:Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surg 25:186-188, 1994
8)Shin MJ, Liao SL, Lu HY:A single transcutaneous injection with Botox for dysthyroid lid retraction. Eye 18:466-469, 2004
9)Morgenstern KE, Evanchan J, Foster JA et al:Botulinum toxin type A for dysthyroid upper eyelid retraction. Ophthal Plast Reconstr Surg 20:181-185,2004